---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-024661"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2024-06-21T23:59:59+00:00"
generated_at: "2026-06-01T03:05:02.059745+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Provectus shareholders approve reverse stock split authorization and other proposals at annual meeting

## Summary
- All six proposals passed at June 20, 2024 annual meeting; directors elected with >96% votes cast.
- Reverse stock split (1:10 to 1:50) authorized with 302.9M for (92.4%); authorized share reduction also approved.
- Advisory vote on executive compensation passed with 202.8M for (96.6%); broker non-votes 115.0M.
- Marcum LLP ratified as auditor for 2024 with 325.7M for (99.6%); no broker non-votes.
- 2024 Equity Compensation Plan approved with 198.3M for (94.0%); broker non-votes 115.0M.

## SEC filing metadata
- accession: 0001493152-24-024661
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2024-06-21T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315224024661/0001493152-24-024661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315224024661/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-024661
- JSON: https://secwatch.observer/filing/0001493152-24-024661.json
- Plain text: https://secwatch.observer/filing/0001493152-24-024661.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.